Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations
Latest Information Update: 06 Jun 2019
At a glance
- Drugs BTRX 246040 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors BlackThorn Therapeutics
- 03 Jun 2019 Status changed from recruiting to completed.
- 25 Mar 2019 Planned number of patients changed from 32 to 24.
- 25 Mar 2019 Planned End Date changed from 1 Feb 2019 to 30 May 2019.